Presentation is loading. Please wait.

Presentation is loading. Please wait.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan.

Published byAku Jurkka Modified over 5 years ago

Similar presentations

Presentation on theme: "Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan."— Presentation transcript:

1 Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan Feng, MD, PhD, Arun D. Singh, MD, Christopher Lanigan, MS, Raymond R. Tubbs, DO, Patrick C. Ma, MD  Journal of Thoracic Oncology  Volume 8, Issue 12, Pages e109-e111 (December 2013) DOI: /01.JTO b Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Retinal images and ocular ultrasonography of patient’s left (L) and right (R) eye at diagnosis (1A, top) and after 10 months of crizotinib therapy (1B, bottom). Journal of Thoracic Oncology 2013 8, e109-e111DOI: ( /01.JTO b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 PET/CT scans indicating patient’s left lower lobe mass and left hilar adenopathy at diagnosis (2A), progression after 5 months of erlotinib (2B) and complete response after 14 months of crizotinib (2C). Journal of Thoracic Oncology 2013 8, e109-e111DOI: ( /01.JTO b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 ALK immunohistochemistry (IHC) expression analysis on patient’s tumor (left: 4X, right: 20X). Journal of Thoracic Oncology 2013 8, e109-e111DOI: ( /01.JTO b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer  Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,

A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer  Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
ALK Status Testing in Non–Small Cell Lung Carcinoma

ALK Status Testing in Non–Small Cell Lung Carcinoma
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 

Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Interpretation of Anti-ALK Immunohistochemistry Results

Interpretation of Anti-ALK Immunohistochemistry Results

Similar presentations

Ads by Google